Potential anti-catabolic and anabolic properties of strontium ranelate

Current Molecular Pharmacology

Volumn 5, Issue 2, 2012, Pages 189-194

  Mentaverri, Romuald ^a   Brazier, Michel ^a,b   Kamel, Said ^a,b   Fardellone, Patrice ^a,b  

^a INSERM   (France)

^b AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

Biological markers; Bone cells activity; Bone remodeling; Strontium Ranelate

Indexed keywords

PLACEBO; STRONTIUM RANELATE;

BIOSYNTHESIS; BONE DENSITY; BONE METABOLISM; BONE MINERALIZATION; BONE REMODELING; CHEMICAL ANALYSIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; OSTEOCLAST; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW;

EID: 84861759196     PISSN: 18744672     EISSN: 18744702     Source Type: Journal    
DOI: 10.2174/1874467211205020189     Document Type: Review

References (37)

1. Manolagas, S.C. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev., 2000, 21, 115-137.
2. Downey, P.A.; Siegel, M.I. Bone biology and the clinical implications for osteoporosis. Phys. Ther., 2006, 86, 77-91.
3. Ruppel, M.E.; Miller, L.M.; Burr, D.B. The effect of the microscopic and nanoscale structure on bone fragility. Osteoporos. Int., 2008, 19, 1251-1265.
4. Doggrell, S.A. Recent important clinical trials of drugs in osteoporosis. Expert Opin. Pharmacother., 2004, 5, 1635-1638.
5. Meunier, P.J.; Roux, C.; Seeman, E.; Ortolani, S.; Badurski, J.E.; Spector, T.D.; Cannata, J.; Balogh, A.; Lemmel, E. M.; Pors-Nielsen, S.; Rizzoli, R.; Genant, H.K.; Reginster, J.Y. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med., 2004, 350, 459-468.
6. Reginster, J.Y.; Seeman, E.; De Vernejoul, M.C.; Adami, S.; Compston, J.; Phenekos, C.; Devogelaer, J.P.; Curiel, M.D.; Sawicki, A.; Goemaere, S.; Sorensen, O.H.; Felsenberg, D.; Meunier, P.J. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J. Clin. Endocrinol. Metab., 2005, 90, 2816-2822.
7. Roux, C.; Reginster, J.Y.; Fechtenbaum, J.; Kolta, S.; Sawicki, A.; Tulassay, Z.; Luisetto, G.; Padrino, J.M.; Doyle, D.; Prince, R.; Fardellone, P.; Sorensen, O.H.; Meunier, P.J. Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J. Bone Miner. Res., 2006, 21, 536-542.
8. Marie, P.J. Strontium ranelate: a physiological approach for optimizing bone formation and resorption. Bone, 2006, 38, S10-14.
9. Marie, P.J. Strontium ranelate: a dual mode of action rebalancing bone turnover in favour of bone formation. Curr. Opin. Rheumatol., 2006, 18(Suppl. 1), S11-15.
10. Ammann, P. Strontium ranelate: a physiological approach for an improved bone quality. Bone, 2006, 38, 15-18.
11. Baroukh, B.; Cherruau, M.; Dobigny, C.; Guez, D.; Saffar, J.L. Osteoclasts differentiate from resident precursors in an in vivo model of synchronized resorption: a temporal and spatial study in rats. Bone, 2000, 27, 627-634.
12. Roodman, G.D. Cell biology of the osteoclast. Exp. Hematol., 1999, 27, 1229-1941.
13. Mulari, M.T.; Qu, Q.; Harkonen, P.L.; Vaananen, H.K. Osteoblastlike cells complete osteoclastic bone resorption and form new mineralized bone matrix in vitro. Calcif. Tissue Int., 2004, 75, 253-261.
14. Simon, L.S. Osteoporosis. Clin. Geriatr. Med., 2005, 21, 603-629, viii.
15. Bonnick, S.L.; Shulman, L. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am. J. Med., 2006, 119, S25-31.
16. Recker, R.R.; Marin, F.; Ish-Shalom, S.; Moricke, R.; Hawkins, F.; Kapetanos, G.; de la Pena, M.P.; Kekow, J.; Farrerons, J.; Sanz, B.; Oertel, H.; Stepan, J. Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. J. Bone Miner. Res., 2009, 24, 1358-1368.
17. Bruyere, O.; Collette, J.; Rizzoli, R.; Decock, C.; Ortolani, S.; Cormier, C.; Detilleux, J.; Reginster, J.Y. Relationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years. Osteoporos. Int., 21, 1031-1036.
18. Ammann, P.; Shen, V.; Robin, B.; Mauras, Y.; Bonjour, J.P.; Rizzoli, R. Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats. J. Bone Miner. Res., 2004, 19, 2012-2020.
19. Arlot, M.E.; Jiang, Y.; Genant, H.K.; Zhao, J.; Burt-Pichat, B.; Roux, J.P.; Delmas, P.D.; Meunier, P.J. Histomorphometric and microCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate. J. Bone Miner. Res., 2008, 23, 215-222.
20. Middleton, E.T.; Steel, S.A.; Aye, M.; Doherty, S.M. The effect of prior bisphosphonate therapy on the subsequent BMD and bone turnover response to strontium ranelate. J. Bone Miner. Res., 2010, 25, 455-462.
21. Buehler, J.; Chappuis, P.; Saffar, J.L.; Tsouderos, Y.; Vignery, A. Strontium ranelate inhibits bone resorption while maintaining bone formation in alveolar bone in monkeys (Macaca fascicularis). Bone, 2001, 29, 176-179.
22. Farlay, D.; Boivin, G.; Panczer, G.; Lalande, A.; Meunier, P.J. Long-term strontium ranelate administration in monkeys preserves characteristics of bone mineral crystals and degree of mineralization of bone. J. Bone Miner. Res., 2005, 20, 1569-1578.
23. Marie, P.J.; Hott, M.; Modrowski, D.; De Pollak, C.; Guillemain, J.; Deloffre, P.; Tsouderos, Y. An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J. Bone Miner. Res., 1993, 8, 607-615.
24. Boivin, G.; Farlay, D.; Khebbab, M.T.; Jaurand, X.; Delmas, P.D.; Meunier, P.J. In osteoporotic women treated with strontium ranelate, strontium is located in bone formed during treatment with a maintained degree of mineralization. Osteoporos. Int., 2010, 21, 667-677.
25. Pors Nielsen, S.; Barenholdt, O.; Diessel, E.; Armbrust, S.; Felsenberg, D. Linearity and accuracy errors in bone densitometry. Br. J. Radiol., 1998, 71, 1062-1068.
26. Canalis, E.; Hott, M.; Deloffre, P.; Tsouderos, Y.; Marie, P.J. The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone, 1996, 18, 517-523.
27. Atkins, G.J.; Welldon, K.J.; Halbout, P.; Findlay, D.M. Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response. Osteoporos. Int., 2008, 20, 653-664.
28. Baron, R.; Tsouderos, Y. In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation. Eur. J. Pharmacol., 2002, 450, 11-17.
29. Bonnelye, E.; Chabadel, A.; Saltel, F.; Jurdic, P. Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. Bone, 2008, 42, 129-138.
30. Caudrillier, A.; Hurtel-Lemaire, A.S.; Wattel, A.; Cournarie, F.; Godin, C.; Petit, L.; Petit, J.P.; Terwilliger, E.; Kamel, S.; Brown, E.M.; Mentaverri, R.; Brazier, M. Strontium ranelate decreases RANKL-induced osteoclastic differentiation in vitro: involvement of the calcium sensing receptor. Mol. Pharmacol., 2010, 78(4), 567-569.
31. Chattopadhyay, N.; Yano, S.; Tfelt-Hansen, J.; Rooney, P.; Kanuparthi, D.; Bandyopadhyay, S.; Ren, X.; Terwilliger, E.; Brown, E.M. Mitogenic action of calcium-sensing receptor on rat calvarial osteoblasts. Endocrinology, 2004, 145, 3451-3462.
32. Mentaverri, R.; Yano, S.; Chattopadhyay, N.; Petit, L.; Kifor, O.; Kamel, S.; Terwilliger, E.F.; Brazier, M.; Brown, E.M. The calcium sensing receptor is directly involved in both osteoclast differentiation and apoptosis. FASEB J., 2006, 20, 2562-2564.
33. Caverzasio, J. Strontium ranelate promotes osteoblastic cell replication through at least two different mechanisms. Bone, 2008, 42, 1131-1136.
34. Fromigue, O.; Hay, E.; Barbara, A.; Petrel, C.; Traiffort, E.; Ruat, M.; Marie, P.J. Calcium sensing receptor-dependent and receptorindependent activation of osteoblast replication and survival by strontium ranelate. J. Cell. Mol. Med., 2009, 13, 2189-2199.
35. Fromigue, O.; Hay, E.; Barbara, A.; Marie, P.J. Essential role of nuclear factor of activated T cells (NFAT)-mediated Wnt signaling in osteoblast differentiation induced by strontium ranelate. J. Biol. Chem., 2010, 285, 25251-25258.
36. Brennan, T.; Rybchyn, M.; Green, W.; Atwa, S.; Conigrave, A.; Mason, R. Osteoblasts play key roles in the mechanisms of action of strontium ranelate. Br. J. Pharmacol., 2009, 157, 1291-1300.
37. Hurtel-Lemaire, A.S.; Mentaverri, R.; Caudrillier, A.; Cournarie, F.; Wattel, A.; Kamel, S.; Terwilliger, E.F.; Brown, E.M.; Brazier, M. The calcium-sensing receptor is involved in strontium ranelateinduced osteoclast apoptosis. New insights into the associated signaling pathways. J. Biol. Chem., 2009, 284, 575-584.